| Literature DB >> 27306074 |
Reena Khanna1, Nilesh Chande, Séverine Vermeire, William J Sandborn, Claire E Parker, Brian G Feagan.
Abstract
Multiple new biological treatments for Crohn's disease and ulcerative colitis are becoming available. Specifically, vedolizumab and ustekinumab are monoclonal antibodies that target molecular pathways relevant to disease pathogenesis. What can Cochrane reviews tell us about the efficacy, safety, and immunogenicity of these new agents? A Cochrane inflammatory bowel disease group symposium held at the 2015 Digestive Diseases Week annual meeting addressed these questions. This article reviews the data presented at that session.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27306074 DOI： 10.1097/MIB.0000000000000808
Source DB: PubMed Journal: Inflamm Bowel Dis ISSN： 1078-0998 Impact factor: 5.325